sunvozertinib
dizal pharmaceuticals
['sunvozertinib', 'sclc', 'lcsm,(-blcsm)', 'nsclc']
promising phase 2 multi-center study in china of sunvozertinib in previously treated #nsclc patients with egfr exon20ins showed anti-tumor efficacy in &gt;90% of pts treated. orr was 60.8% with activity across exon20ins subtypes. phase 2 multinational study is ongoing. #asco23 #lcsm 
LUNGevity, the nation’s leading lung cancer organization, is transforming what it means to be diagnosed and live with lung cancer.